Open AccessA randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Author(s) -
Pauline Thompson,
Philip E. Aylward,
J. Federman,
R. Giles,
Phillip J. Harris,
RL Hodge,
G. Nelson,
A. G. Thomson,
Andrew Tonkin,
Warren Walsh
Publication year - 1991
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.83.5.1534
Subject(s) - medicine , dipyridamole , heparin , myocardial infarction , timi , aspirin , cardiology , ejection fraction , thrombolysis , anesthesia , radionuclide ventriculography , streptokinase , cardiac catheterization , coronary artery disease , heart failure
This study addressed the need for heparin administration to be continued for more than 24 hours after coronary thrombolysis with recombinant tissue-type plasminogen activator (rt-PA).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom